PARP16 is a druggable regulator of ribosome MARylation and protein homeostasis in ovarian cancer cells
Journal of Biological Chemistry · 2026
DOI: 10.1016/j.jbc.2026.113540 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Sridevi Challa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medica…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Ribosomes, Poly(ADP-ribose) Polymerases, Proteostasis. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Congressionally Directed Medical Research Programs, Cecil H. and Ida Green Center for Reproductive Biology Sciences, National Institutes of Health.
Abstract (Originalsprache)
Cytosolic NAD+ synthesis supports ovarian cancer growth by enabling PARP16-dependent mono(ADP-ribosyl)ation (MARylation) of ribosomal proteins, thereby fine-tuning translation and maintaining protein homeostasis. While genetic depletion of PARP16 disrupts ribosome MARylation and impairs tumor cell growth, the therapeutic potential of pharmacologic PARP16 inhibition in this pathway remains unexplored. Here, we characterized the effects of DB008, a tool compound that functions as a selective inhibitor of PARP16, in ovarian cancer cells. Biochemical analyses demonstrated that PARP16 undergoes NAD+-dependent autoMARylation and that NMNAT-2 supplies NAD+ to support this activity. DB008 potently inhibited PARP16 autoMARylation in vitro. In ovarian cancer cells, DB008 engaged PARP16, reduced its MARylation, and decreased ribosome-associated MARylation. Consistent with PARP16 depletion, DB008 enhanced global protein synthesis, increased protein aggregation, and suppressed cell growth and anchorage-independent colony formation. CRISPR-mediated deletion of the PARP16 gene in ovarian cancer cells abolished the effects of DB008 on translation, protein aggregation, and proliferation, demonstrating on-target activity. Moreover, cells expressing a PARP16 mutant resistant to DB008 were unaffected by inhibitor treatment, further confirming that the cellular effects of DB008 require on-target inhibition. Finally, DB008 significantly inhibited tumor growth in OVCAR3 xenografts, with on-target engagement of PARP16 in the xenograft tumors. Collectively, these findings establish PARP16 as a druggable regulator of ribosome MARylation and protein homeostasis in ovarian cancer and provide pharmacologic proof-of-concept that disrupting ribosomal MARylation impairs tumor growth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Section of Laboratory Research, Departme…
Förderung
- Congressionally Directed Medical Research Programs
- Cecil H. and Ida Green Center for Reproductive Biology Sciences
- National Institutes of Health
- US Department of War
Zitieren
APA
Challa, S., Dasovich, M., Abshier, J. C., Pekhale, K., Yang, L., Camacho, C. V., & Kraus, W. L. (2026). PARP16 is a druggable regulator of ribosome MARylation and protein homeostasis in ovarian cancer cells. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.113540
Vancouver
Challa S, Dasovich M, Abshier JC, Pekhale K, Yang L, Camacho CV, et al. PARP16 is a druggable regulator of ribosome MARylation and protein homeostasis in ovarian cancer cells. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.113540
BibTeX
@article{Challa2026,
author = {Challa, Sridevi and Dasovich, Morgan and Abshier, Jonathan C and Pekhale, Komal and Yang, Lu and Camacho, Cristel V and Kraus, W Lee},
title = {PARP16 is a druggable regulator of ribosome MARylation and protein homeostasis in ovarian cancer cells},
journal = {Journal of Biological Chemistry},
year = {2026},
doi = {10.1016/j.jbc.2026.113540}
}
EUVIMED